Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features

Documenti analoghi

• Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation
  di: Weiping Jia, et al.
  Pubblicazione: (2025)
• Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
  di: Stergios A. Polyzos, et al.
  Pubblicazione: (2026)
• Efsubaglutide alfa in adults with overweight or obesity: Protocol for a seamless, adaptive phase 2b/3 randomized, double‐blind, placebo‐controlled trial ( LIGHT 2)
  di: Weiping Jia, et al.
  Pubblicazione: (2026)
• Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
  di: Fei Gao, et al.
  Pubblicazione: (2026)
• A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
  di: James Kim, et al.
  Pubblicazione: (2025)